Steven Cohen Astria Therapeutics, Inc. Transaction History
Point72 Asset Management, L.P.
- $44.6 Billion
- Q2 2025
A detailed history of Steven Cohen (Point72 Asset Management, L.P.) transactions in Astria Therapeutics, Inc. stock. As of the latest transaction made, Point72 Asset Management, L.P. holds 762,756 shares of ATXS stock, worth $5.07 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
762,756Holding current value
$5.07 Million% of portfolio
0.01%Shares
3 transactions
Others Institutions Holding ATXS
# of Institutions
110Shares Held
49.3MCall Options Held
6.6KPut Options Held
0-
Perceptive Advisors LLC New York, NY6.49MShares$43.1 Million1.53% of portfolio
-
Vestal Point Capital, LP New York, NY4.52MShares$30.1 Million1.28% of portfolio
-
Fcpm Iii Services B.V. Naarden, P74.11MShares$27.3 Million6.34% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.55MShares$23.6 Million5.84% of portfolio
-
Black Rock Inc. New York, NY3.52MShares$23.4 Million0.0% of portfolio
About Astria Therapeutics, Inc.
- Ticker ATXS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,178,000
- Market Cap $101M
- Description
- Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare and niche allergic, and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in preclinical development stage...